Mission

Our mission

IN VIRTUO mission aims to create and distribute virtual reality software developed by experienced clinicians to health professionals to assist during gradual exposure exercises included in a cognitive-behavioral therapy to treat anxiety disorders and other mental health issues.

Our team, in collaboration with the Canada Research Chair in Clinical Cyberpsychology, is developing virtual reality software in hope of making this technology accessible at a lower cost.

Since 2021, C2Care is our trusted exclusive distributor. For more information about our software and access conditions, contact C2Care by email: sales@c2.care or visit their website.

Background

2007
July 10th, 2007

Incorporation of the company

2008-2017
2008-2017

IN VIRTUO software development including scientific validation at UQO
Development and validation of virtual environments through research at the Cyberpsychology Lab of UQO.

Partnership and agreement with UQO to transfer the technology to In Virtuo (who became a « spin-off » company). These agreements allow In Virtuo to commercially promote and disseminate the 3D software developed while conducting research at UQO.

October 27, 2009

Grand opening of our clinic (psychotherapy)

2017-2018
2017

Ministère de l’Économie, de la Science et de l’Innovation (MESI). Financial grant of 43 400$ to market and export In Virtuo software in foreign countries.

2017

Développement Économique Canada. Financial loan granted, free of interest, to export our products in foreign countries.

2018

Certification by Health Canada as Manufacture Devices for Distribution – Class I.
Also satisfies directives from the EU has medical devices CE – Class I.

2021

C2Care becomes the exclusive distributor of IN VIRTUO software.

In Virtuo and research

In Virtuo works in collaboration with the Canada research Chair in clinical cyberpsychology held by In Virtuo’s President and full professor at the Université du Québec en Outaouais (UQO), Dr Stéphane Bouchard, and aims to create and distribute new virtual reality applications developed by and for clinicians.  All industrial innovations, discoveries and clinical expertise of our management team are validated through scientific research at the Cyberpsychology Lab of UQO.

For more information about ongoing research projects at the Cyberpsychology Lab of UQO and the possibility to participate for free, visit the Cyberpsychology Lab of UQO’s website. Some conditions applies.

Medical Device Establishment Licence Class I (Health Canada - 7695)

Meets requirements of FDA (USA) and CE Marking as Class I medical device (Europe).